Grant: Discovery Grants Program - Individual
The University of British Columbia
$45,000.00
Cellular and molecular biology underlying priming of the immune system
EF 2023-24
Résumé
BACKGROUND: Antigen cross-presentation is an exquisitely essential event leading to the activation of virtually all primary cell-mediated immunity of cytotoxic T lymphocytes (CTL), and as such, a major target for developing new clinical tools for immune disorders, including better-performing vaccines. Conventional knowledge contends that dendritic cells (DCs) are unique in their ability to process extracellular antigens for presentation by major histocompatibility complex class 1 (MHC-I). However, we recently challenged this notion by demonstrating that type 2 innate lymphoid cells (ILC2s) also possess a specialized MHC-I antigen cross-presenting ability that is critical for stimulating primary TH1-regulated CTL responses. In addition, they are beneficial in suppressing cancer growth and metastasis. The main goal of this project is to develop a molecular understanding to further unravel the novel role of DCs and ILC2s in cross-presentation and cross-priming of cytolytic T-cells, with important translational implications for the development of new anti-cancer strategies and more effective vaccines. SCIENTIFIC APPROACH: Mouse primary DCs and ILC2s will be isolated and cultured in vitro, then transduced with the CRISPR-Cas9 system, then screened for genes involved in cross-presentation. Mutants will be selected on the basis of cross-presented antigens, measured using antibody binding, in vitro cross-presentation and cross-priming assays. We will confirm the function of individual genes in cross-presentation by evaluating the ability of the specific targeted CRISPR-mutated candidate genes and genetic complementation in CRISPR-Cas9 mutated DCs and ILC2s. Single-cell RNA sequencing, flow cytometry, immunohistochemistry, confocal microscopy, Western blotting, and RT-PCR will also be used to validate these targets. Finally, pathway analysis of genes differentially-expressed by DCs and ILC2s will allow for an understanding of the functional differences between these cell types. These experiments will be instrumental in uncovering the molecular details of MHC-I cross-presentation in both DCs and ILC2s, and will complement ongoing research in our laboratory to understand the role of ILC2s in the immune system. ANTICIPATED OUTCOMES AND BENEFITS: Elucidating the unique and shared molecular details of MHC-I presentation by DCs and ILC2s has extensive clinical implications, ranging from allergy and autoimmunity to infection and cancer. It will also provide a starting point to investigate the immune system interactions of organisms other than humans and mice. Therefore, understanding pathways of cross-presentation by DCs and ILC2s, their similarities and differences, opens the door for a multitude of new avenues for understanding mammalian immune systems and the results of these studies have the potential to be translated into new anti-cancer treatments and novel, more effective vaccines.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2023-06035
Name nom
Jefferies, Wilfred
Department département
Michael Smith Laboratories
Organization id
2
Institution établissement
The University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
45000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Immunology
Research subject en
Microbiologie
Research subject fr
Immunologie
Application title
Cellular and molecular biology underlying priming of the immune system
Keyword
CRISPR-Cas9; Cross presentation; Cross Priming; Dendritic cells; ILC2; Immunity; T-Cells
Application summary
BACKGROUND: Antigen cross-presentation is an exquisitely essential event leading to the activation of virtually all primary cell-mediated immunity of cytotoxic T lymphocytes (CTL), and as such, a major target for developing new clinical tools for immune disorders, including better-performing vaccines. Conventional knowledge contends that dendritic cells (DCs) are unique in their ability to process extracellular antigens for presentation by major histocompatibility complex class 1 (MHC-I). However, we recently challenged this notion by demonstrating that type 2 innate lymphoid cells (ILC2s) also possess a specialized MHC-I antigen cross-presenting ability that is critical for stimulating primary TH1-regulated CTL responses. In addition, they are beneficial in suppressing cancer growth and metastasis. The main goal of this project is to develop a molecular understanding to further unravel the novel role of DCs and ILC2s in cross-presentation and cross-priming of cytolytic T-cells, with important translational implications for the development of new anti-cancer strategies and more effective vaccines. SCIENTIFIC APPROACH: Mouse primary DCs and ILC2s will be isolated and cultured in vitro, then transduced with the CRISPR-Cas9 system, then screened for genes involved in cross-presentation. Mutants will be selected on the basis of cross-presented antigens, measured using antibody binding, in vitro cross-presentation and cross-priming assays. We will confirm the function of individual genes in cross-presentation by evaluating the ability of the specific targeted CRISPR-mutated candidate genes and genetic complementation in CRISPR-Cas9 mutated DCs and ILC2s. Single-cell RNA sequencing, flow cytometry, immunohistochemistry, confocal microscopy, Western blotting, and RT-PCR will also be used to validate these targets. Finally, pathway analysis of genes differentially-expressed by DCs and ILC2s will allow for an understanding of the functional differences between these cell types. These experiments will be instrumental in uncovering the molecular details of MHC-I cross-presentation in both DCs and ILC2s, and will complement ongoing research in our laboratory to understand the role of ILC2s in the immune system. ANTICIPATED OUTCOMES AND BENEFITS: Elucidating the unique and shared molecular details of MHC-I presentation by DCs and ILC2s has extensive clinical implications, ranging from allergy and autoimmunity to infection and cancer. It will also provide a starting point to investigate the immune system interactions of organisms other than humans and mice. Therefore, understanding pathways of cross-presentation by DCs and ILC2s, their similarities and differences, opens the door for a multitude of new avenues for understanding mammalian immune systems and the results of these studies have the potential to be translated into new anti-cancer treatments and novel, more effective vaccines.